CA3111114A1 - Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide - Google Patents

Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide Download PDF

Info

Publication number
CA3111114A1
CA3111114A1 CA3111114A CA3111114A CA3111114A1 CA 3111114 A1 CA3111114 A1 CA 3111114A1 CA 3111114 A CA3111114 A CA 3111114A CA 3111114 A CA3111114 A CA 3111114A CA 3111114 A1 CA3111114 A1 CA 3111114A1
Authority
CA
Canada
Prior art keywords
type
xrpd
shows
purity
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111114A
Other languages
English (en)
French (fr)
Inventor
Xiangyang Chen
Zuopeng WANG
Liqin YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of CA3111114A1 publication Critical patent/CA3111114A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3111114A 2018-09-18 2019-09-18 Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide Pending CA3111114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732994P 2018-09-18 2018-09-18
US62/732,994 2018-09-18
PCT/CN2019/106433 WO2020057549A1 (en) 2018-09-18 2019-09-18 Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide

Publications (1)

Publication Number Publication Date
CA3111114A1 true CA3111114A1 (en) 2020-03-26

Family

ID=69888278

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111114A Pending CA3111114A1 (en) 2018-09-18 2019-09-18 Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide

Country Status (11)

Country Link
US (1) US11945792B2 (https=)
EP (1) EP3853217B1 (https=)
JP (1) JP2022501351A (https=)
KR (1) KR20210060501A (https=)
CN (2) CN112654607B (https=)
AU (1) AU2019341284B2 (https=)
CA (1) CA3111114A1 (https=)
ES (1) ES2951420T3 (https=)
MX (1) MX2021003064A (https=)
SG (1) SG11202102116XA (https=)
WO (1) WO2020057549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894440B (zh) * 2022-10-27 2024-10-22 都创(重庆)医药科技有限公司 奥布替尼化合物的晶型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
KR102272792B1 (ko) * 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
SG11201704808VA (en) * 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery

Also Published As

Publication number Publication date
JP2022501351A (ja) 2022-01-06
CN116496247A (zh) 2023-07-28
AU2019341284A1 (en) 2021-04-15
CN112654607B (zh) 2023-01-13
EP3853217A1 (en) 2021-07-28
WO2020057549A1 (en) 2020-03-26
EP3853217B1 (en) 2023-06-07
US11945792B2 (en) 2024-04-02
CN112654607A (zh) 2021-04-13
AU2019341284B2 (en) 2024-09-05
KR20210060501A (ko) 2021-05-26
SG11202102116XA (en) 2021-04-29
ES2951420T3 (es) 2023-10-20
US20210188801A1 (en) 2021-06-24
MX2021003064A (es) 2021-05-27
EP3853217A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
CA2963581C (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
RU2607083C2 (ru) Кристалл циклопептида высокой чистоты, а также способ его получения и его применение
CN112805065B (zh) 磺酰胺结构的激酶抑制剂的新盐酸盐形式
EA036874B1 (ru) Новые соли и полиморфы scy-078
US11945792B2 (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide
RS82504A (sr) Izostrukturni pseudopolimorfi 9-deokso-9a-aza-9a-metil-9a-homoeritromicin a
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
MXPA02000033A (es) Polimorfos de un diclorhidrato cristalino de azobiciclo (2, 2, 2)oct-3-ilamina y sus composiciones farmaceuticas.
JP2013184902A (ja) リファキシミン含有結晶
ES3034394T3 (en) Salt of s-oxprenolol
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
HK40048993B (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
HK40048993A (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
AU2016236659B2 (en) AHU377 crystal form, preparation method and use thereof
HK40096475A (zh) 6-(1-丙烯醯基哌啶-4-基)-2-(4-苯氧基苯基)尼克醯胺的晶型
AU2012283277B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
TW202102510A (zh) 呋喃嘧啶化合物酸加成鹽之晶形及藥物組成物
TWI876245B (zh) (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形
KR20180124400A (ko) 사쿠비트릴 결합체, 이의 제조방법 및 이를 포함하는 약학 조성물
CA3186319A1 (en) Crystal forms of crenolanib and methods of use thereof
HK40107533A (zh) (2r，3s)-2-(3-(4，5-二氯-1h-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
HK40050950B (zh) 磺酰胺结构的激酶抑制剂的新盐酸盐形式

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240826

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240829

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240829

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D141 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CONDITIONAL ALLOWANCE

Effective date: 20260303

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260303